CELGENE CORP /DE/
Form 8-K June 28, 2018
Julie 28, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 28, 2018

# **CELGENE CORPORATION**

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$ 

Delaware (State or other jurisdiction	001-34912 (Commission	22-2711928 (IRS Employer
of incorporation)		Identification No.)
86 Morris Avenue, Summit	,	07901
New Jersey (Address of principal executive offices)		(Zip Code)
Registrant's telephone num	ber, including	area code: (908) 673-9000
(Former name or former ad	ldress, if chang	ed since last report.)
Check the appropriate box be the registrant under any of the		8-K filing is intended to simultaneously satisfy the filing obligation of visions:
"Written communications pur	rsuant to Rule 4	25 under the Securities Act (17 CFR 230.425)
"Soliciting material pursuant	to Rule 14a-12	under the Exchange Act (17 CFR 240.14a-12)
"Pre-commencement commu	nications pursua	ant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
"Pre-commencement commu	nications pursua	ant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
	-	t is an emerging growth company as defined in Rule 405 of the Securities 2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company "

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

#### **ITEM 8.01**

#### **OTHER EVENTS**

On June 28, 2018, Celgene Corporation announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo.

Attached hereto and incorporated by reference as Exhibit 99.1 is the Press Release announcement.

## ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit 99.1 – Press Release dated June 28, 2018

## **SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## **CELGENE CORPORATION**

Date: June 28, 2018 By: /s/ Peter N. Kellogg

Peter N. Kellogg

Executive Vice President and Chief Financial Officer

(principal financial and accounting officer)